Reports Q4 revenue $13.7M, consensus $12.62M. “We are exceptionally pleased with our financial performance in 2023, as it marked a year of continued strong growth for our company. Our year-over-year revenue grew by 24%, and our adjusted EBITDA increased by 21%. Notably, plasma revenue also grew by 21%. Additionally, our patient affordability business has emerged as a significant growth driver, experiencing an impressive 172% revenue growth,” stated Mark Newcomer, President & CEO of Paysign. “Looking ahead to the current year, we anticipate continued upward trajectory across all our business units. Our patient affordability business in particular, is poised for triple-digit year-over-year growth. Our patient affordability solutions have gained traction among major players in the pharmaceutical industry, and our robust pipeline positions us well for the future. We are strategically leveraging recent disruptions in the pharmaceutical payments space to our advantage. Our unwavering commitment to sustainable top and bottom-line growth remains steadfast. We firmly believe that our ongoing investments in this business unit will play a pivotal role in delivering long-term shareholder value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Fly Insider: NextNav, Akamai among week’s notable insider trades
- Paysign price target raised to $4 from $3 at DA Davidson
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- Is PAYS a Buy, Before Earnings?
- Fly Insider: Crocs, Best Buy among week’s notable insider trades